NewsCBDUS Regulators Acknowledge CBD Is Here To Stay

US Regulators Acknowledge CBD Is Here To Stay

-

FOLLOWING last November’s CBD broadside signs of a more conciliatory tone have emerged from US regulators in recent weeks.

Last November, the US Food and Drug Administration (FDA) issued an interim warning on the potential harmful effects of CBD.

It said it was seeking answers to questions about the science, safety, and quality of products containing CBD, saying: “The FDA is concerned that people may mistakenly believe that trying CBD can’t hurt.

“The agency wants to be clear that we have seen only limited data about CBD’s safety and these data point to real risks that need to be considered.

However, in early March FDA Commissioner Stephen Hahn, MD, acknowledged the US CBD industry is here to stay.

He said: “We’re not going to be able to say you can’t use these products. It’s a fools errand to even approach that. 

“We have to be open to the fact that there might be some value to these products and certainly Americans think that’s the case. But we want to get them information to make the right decisions.”

In a press statement released around the same time the FDA’s moderated tone became apparent when said it was seeking to ‘educate consumers about the number of questions that remain regarding CBD’s safety’.

While re-iterating it concerns over potential liver damage, male reproductive toxicity, sustained use, drug interactions and its effect on ‘vulnerable groups’ it went on to say that it ‘doesn’t know if CBD is unsafe to these populations’.

Its said it wants to see further research into CBD usage including the sedative effects of CBD; the impacts of long-term sustained or cumulative exposure to CBD;  different administration methods and the safety of CBD for use in pets and food-producing animals. 

It is also interested in learning more about full and broad spectrum hemp extracts and CBD isolates, it says.

It concluded: “We recognize the significant public interest in CBD and we must work together with stakeholders and industry to develop high-quality data to close the substantial knowledge gaps about the science, safety and quality of many of these products.”

While this latest update offers no sign of a speedy resolution to the US CBD regulatory quagmire it does appear that the FDA is taking its foot of its anti-CBD accelerator.

However, for those businesses making illegal medical claims and selling product contaminants such as heavy metals, THC or other potentially harmful substances, it went on to say there will be no let up on the enforcement front.


Peter
Peter McCusker is an experienced news and business editor, who believes it’s time to fully embrace the multiple, proven, medical benefits of the cannabis plant.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest news

Industry Concerns Surface Over No 10 Taskforce’s Hemp And Cannabis Proposals

THE initial warm welcome to proposals to make UK cannabinoid regulations a matter for the health authorities - not...

IM Cannabis Clinical Survey Confirms Effectiveness of Proprietary Strains in Alleviating Symptoms of Seven Key Health Conditions

IM Cannabis Corp. ("IMC" or the "Company") (NASDAQ:IMCC, CSE:IMCC), a multi-country operator ("MCO") in the medical and adult-use recreational...

Always Pure Organics Makes £3m Continental Swoop For Leading B2C Hemp And CBD Player

FAST-GROWING UK cannabis wholesaler Always Pure Organics has acquired two Belgian companies - Distribution Legal Hemp and NexGen -...

Little Green Pharma Picks Up Distressed Canadian LP’s Danish Cannabis Asset for £11.6m

AUSTRALIAN company Little Green Pharma has purchased the former Canopy Growth medicinal cannabis cultivation and manufacturing facility in Denmark...

New Era Beckons For Swiss Medical Cannabis Patients After Ten Years In Slow Lane

THE impending change to Switzerland’s medical cannabis laws could see the number of patients receiving treatment rise from 3,000...

How Britain’s Three Crown Dependencies Are Stealing A Cannabis March On the Mainland

FRUSTRATED by the UK Government’s stance the three UK Crown Dependencies of Jersey, Guernsey and the Isle of Man,...

Must read

Industry Concerns Surface Over No 10 Taskforce’s Hemp And Cannabis Proposals

THE initial warm welcome to proposals to make UK...

Little Green Pharma Picks Up Distressed Canadian LP’s Danish Cannabis Asset for £11.6m

AUSTRALIAN company Little Green Pharma has purchased the former...

You might also likeRELATED
Recommended to you